Status:
COMPLETED
Bone Resorption, Osteoclastogenesis and Adalimumab
Lead Sponsor:
Université de Sherbrooke
Collaborating Sponsors:
Abbott
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Osteoclastic bone resorption depends on both the capacity to generate osteoclasts (osteoclastogenesis) and on individual osteoclast activity. The investigators objective is to study the effect of anti...
Detailed Description
Osteoclasts (OCs) are cells specialized in bone degradation that participate in bone and joint destruction in Rheumatoid Arthritis (RA). Experimental models have clearly demonstrated that OCs are esse...
Eligibility Criteria
Inclusion
- Patients satisfying the ACR criteria for Rheumatoid arthritis and having received a prescription of Adalimumab at the Centre Hospitalier Universitaire de Sherbrooke.
Exclusion
- Patients under 18 years old
- Patients unwilling or unable to sign an informed consent
- Patients starting Adalimumab less than five half-lifes after the interruption of a previous anbti-TNF therapy
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00814866
Start Date
September 1 2008
End Date
March 1 2011
Last Update
October 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Recherche Clinique Ethienne Lebel
Fleurimont, Quebec, Canada, J1H 5N4